Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

red_moon_rise In my previous Gritstone bio (NASDAQ:GRTS) article, I discussed how the company’s technology could make it a cutting-edge infectious disease firm with a strong list of collaborations that could rival Moderna (MRNA) and BioNTech (BNTX). However, I also noted that the company's biggest upside potential was its oncology programs, notably GRANITE, which could transform cancer treatment by targeting neoantigens, with encouraging early-stage results. Despite the upside potential, I also pointed  ...